Drug Database
Back to search

Netherlands· NL-4a795cd9d93f

Tandemact 30 mg/2 mg, tabletten

A glimepiride and pioglitazone product containing glimepiride + pioglitazonhydrochloride, registered in Netherlands by CHEPLAPHARM Arzneimittel GmbH. The same ATC class is registered in 10 of our 19 countries.

ATC A10BD06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTandemact 30 mg/2 mg, tablettenATCA10BD06REGISTER NO.NL-4a795cd9d93fPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glimepiride + pioglitazonhydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glimepiride and pioglitazone is registered in 10 of 19 countries.

Countries holding a registration under ATC A10BD06 (glimepiride and pioglitazone), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search glimepiride and pioglitazone products by name

Glimepiride and pioglitazone · ATC A10BD06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GLIMEPIRIDE + PIOGLITAZONHYDROCHLORIDE
Manufacturer
CHEPLAPHARM Arzneimittel GmbH
Country
Netherlands (NL)
ATC code
A10BD06
ATC class
Glimepiride and pioglitazone
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/06/366

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for glimepiride and pioglitazone.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glimepiride and pioglitazone against other medicinesHow interaction checks work

Glimepiride and pioglitazone · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Glimepiride and pioglitazone in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glimepiride and pioglitazone products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tandemact
  • Liechtenstein · Tandemact
  • Norway · Tandemact

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/07c5f182-76fd-422b-86e0-1a49dfbdad61
GET /v1/drugs/07c5f182-76fd-422b-86e0-1a49dfbdad61?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tandemact-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Glimepiride And Pioglitazone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp100472",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROLOSE (E 463)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLYSORBAAT 80 (E 433)"
  ],
  "substances": [
    "GLIMEPIRIDE",
    "PIOGLITAZONHYDROCHLORIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2008/03/31",
  "procedure_number": "EMEA/H/C/000680",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/06/366",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about glimepiride and pioglitazone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console